Intellia Therapeutics (NTLA) has just wrapped enrollment in MAGNITUDE-2, its Phase 3 trial of CRISPR therapy nex-z for hereditary transthyretin amyloidosis with polyneuropathy, drawing fresh attention to the stock’s risk-reward profile.
Recent trading tells a mixed story for Intellia Therapeutics. The share price is down 14.29% over the past week and 21.38% over the last three months. However, the year-to-date share price return of 6.19% sits against a 1-year total shareholder return of 18.69%, while the 3- and 5-year total shareholder returns show steep declines. This indicates that long-term holders have faced heavy volatility, even as the MAGNITUDE-2 milestone and recent earnings continue to reshape how investors weigh risk versus potential reward at the current US$9.78 level.
Scan beyond Intellia Therapeutics and size up other potential rare disease and high-upside opportunities using our hand picked 18 high quality undiscovered gems while this Phase 3 story unfolds.
At roughly US$9.78, Intellia Therapeutics now reflects both a completed Phase 3 enrollment milestone and a long history of volatility. Does that balance of trial risk and upside potential still lean toward new buyers at this price?
The analyst consensus Narrative on Simply Wall St places Intellia Therapeutics at a fair value of $23.11 versus the recent $9.78 close, framing the stock as heavily discounted while tying that view to detailed revenue and earnings forecasts built on a 7.5% discount rate.
The current valuation implies that Intellia Therapeutics is undervalued relative to the potential cash runway into at least 2028, the large rare disease pricing multiples discussed for lonvo z, and the upside some research firms see if nex z proves additive on top of current ATTR standards of care.
See why 90 investors see Intellia Therapeutics as 58% undervalued.
On this set of assumptions, investors are being asked to weigh a $23.11 fair value against a $9.78 price, which implies that the market is heavily discounting regulatory outcomes, payer behavior and long term CRISPR adoption compared with the scenario laid out in the Narrative.
Result: Fair Value of $23.11 (UNDERVALUED)
Still, the whole Intellia Therapeutics story leans heavily on clean late stage data, as well as on payers accepting high upfront pricing for one time CRISPR treatments.
Find out about the key risks to this Intellia Therapeutics narrative.
DCF work and analyst targets lean toward Intellia Therapeutics looking cheap at $9.78. A simple P/S lens tells a different story. The stock trades at 26x sales versus 9.9x for the US Biotechs industry and 7.8x for peers, while the fair ratio sits at just 0.1x. How comfortable are you paying that kind of premium for a business that is still loss making?
That kind of gap between today’s P/S level, the sector, peers and the fair ratio points to real valuation risk if expectations reset closer to more typical multiples. See what the numbers say about this price — find out in our valuation breakdown.
Mixed signals on Intellia Therapeutics can tempt you to wait on the sidelines, yet the real edge comes from testing the numbers yourself and deciding where you land on risk versus upside. To see that full picture in one place, weigh the 2 key rewards and 1 important warning sign.
If Intellia Therapeutics has your attention, do not stop at a single biotech bet when there are other focused ways to hunt for opportunity and manage risk.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com